February 27, 2024
Bristol Myers Squibb on February 26 filed a new drug application for its investigational oral drug ozanimod for the treatment of moderate to severe ulcerative colitis (UC) in Japan, the company said the same day. Ozanimod is a first-in-class sphingosine...read more